Last reviewed · How we verify

Generic Fluorouracil Cream

Actavis Inc. · Phase 3 active Small molecule

Generic Fluorouracil Cream is a Antimetabolite; Pyrimidine analog Small molecule drug developed by Actavis Inc.. It is currently in Phase 3 development for Actinic keratosis (precancerous skin lesions), Superficial basal cell carcinoma, Squamous cell carcinoma in situ. Also known as: 5-FU.

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into DNA and RNA, disrupting nucleotide synthesis and causing cell death in rapidly dividing cells.

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into DNA and RNA, disrupting nucleotide synthesis and causing cell death in rapidly dividing cells. Used for Actinic keratosis (precancerous skin lesions), Superficial basal cell carcinoma, Squamous cell carcinoma in situ.

Likelihood of approval
61.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Oncology Phase 3 boost +3.0pp
    Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameGeneric Fluorouracil Cream
Also known as5-FU
SponsorActavis Inc.
Drug classAntimetabolite; Pyrimidine analog
TargetThymidylate synthase; Thymidine monophosphate synthase
ModalitySmall molecule
Therapeutic areaOncology; Dermatology
PhasePhase 3

Mechanism of action

Fluorouracil (5-FU) acts as an antimetabolite by blocking the enzyme thymidylate synthase, which is essential for DNA synthesis. It also incorporates into RNA, disrupting protein synthesis. As a topical cream formulation, it is used to treat precancerous and cancerous skin lesions by inducing apoptosis in abnormal keratinocytes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Generic Fluorouracil Cream

What is Generic Fluorouracil Cream?

Generic Fluorouracil Cream is a Antimetabolite; Pyrimidine analog drug developed by Actavis Inc., indicated for Actinic keratosis (precancerous skin lesions), Superficial basal cell carcinoma, Squamous cell carcinoma in situ.

How does Generic Fluorouracil Cream work?

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into DNA and RNA, disrupting nucleotide synthesis and causing cell death in rapidly dividing cells.

What is Generic Fluorouracil Cream used for?

Generic Fluorouracil Cream is indicated for Actinic keratosis (precancerous skin lesions), Superficial basal cell carcinoma, Squamous cell carcinoma in situ.

Who makes Generic Fluorouracil Cream?

Generic Fluorouracil Cream is developed by Actavis Inc. (see full Actavis Inc. pipeline at /company/actavis-inc).

Is Generic Fluorouracil Cream also known as anything else?

Generic Fluorouracil Cream is also known as 5-FU.

What drug class is Generic Fluorouracil Cream in?

Generic Fluorouracil Cream belongs to the Antimetabolite; Pyrimidine analog class. See all Antimetabolite; Pyrimidine analog drugs at /class/antimetabolite-pyrimidine-analog.

What development phase is Generic Fluorouracil Cream in?

Generic Fluorouracil Cream is in Phase 3.

What are the side effects of Generic Fluorouracil Cream?

Common side effects of Generic Fluorouracil Cream include Local skin irritation and erythema, Burning and pain at application site, Erosion and ulceration, Photosensitivity, Allergic contact dermatitis.

What does Generic Fluorouracil Cream target?

Generic Fluorouracil Cream targets Thymidylate synthase; Thymidine monophosphate synthase and is a Antimetabolite; Pyrimidine analog.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing